Last reviewed · How we verify
ZG005
At a glance
| Generic name | ZG005 |
|---|---|
| Sponsor | Suzhou Zelgen Biopharmaceuticals Co.,Ltd |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors (PHASE1, PHASE2)
- ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma (PHASE1, PHASE2)
- Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer (PHASE1, PHASE2)
- Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma (PHASE1, PHASE2)
- Study of ZG005 in Patients With Advanced Solid Tumors (PHASE2)
- Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer (PHASE1, PHASE2)
- Study of ZG005 in Combination With Gecacitinib and Chemotherapy for Participants With Advanced Solid Tumors (PHASE1, PHASE2)
- Study of ZG005 in Combination With Platinum-Based Chemotherapy in Participants With Advanced Biliary Tract Carcinoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ZG005 CI brief — competitive landscape report
- ZG005 updates RSS · CI watch RSS
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd portfolio CI